Latest News
Takeda Touts New Exploratory Data from VARSITY Ulcerative Colitis Biologic Study
21 May 2019 - - Japanese pharmaceutical company Takeda Pharmaceutical company Ltd. (TSX: 4502) (NYSE: TAK) has received further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Enty...
Schrödinger Closes USD 110m Financing
21 May 2019 - - Several new investors have joined US-based Schrödinger's latest funding round, which was completed with a total raise of USD 110m to support continued advancement of the company's computational platform and expansion of...
Qiagen Gains 510(k) Clearance by FDA for QIAstat-Dx in the US and Launches System as Next Generation Platform for Syndromic Insights
21 May 2019 - - Dutch life science company Qiagen N.V. (NYSE: QGEN) has undertaken the US launch of its QIAstat-Dx syndromic testing system after receiving 510(k) clearance by the US Food and Drug Administration, along with the multiplex QIAstat-Dx&n...
New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years
21 May 2019 - - US-based pharmaceutical company The Medicines Company (NASDAQ: MDCO) has released interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg...
Gelesis Touts Promising Clinical Data from Pilot Study of Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation
21 May 2019 - - US-based biotechnology company Gelesis has presented data from a clinical study demonstrating that GS500 prototype (GS500/CSP01) provided a significant reduction in colonic transit time in patients with chronic idiopathic constipation...